Document is current
Any future updates will be listed below
-
Authors
Gilchrist, Lachlan
Mutz, Julian
Hysi, Pirro
Legido-Quigley, Cristina
Kõks, Sulev
Lewis, Cathryn M.
Proitsi, Petroula
-
Funding
Funding for this research was provided by:
King’s College London DRIVE-Health Centre for Doctoral Training
Perron Institute for Neurological and Translational Science
King’s Prize Fellowship
NIHR Maudsley Biomedical Research Centre,United Kingdom
Alzheimer’s Research UK
- License Information
-
More Information
Article History
Received: 31 January 2025
Accepted: 14 May 2025
First Online: 2 June 2025
Declarations
:
: This research has been conducted using the UK Biobank Resource under Application Number 82877. Ethical approval for the UK Biobank study has been granted by the National Information Governance Board for Health and Social Care and the NHS North West Multicentre Research Ethics Committee (11/NW/0382). Written informed consent was obtained from all participants by the UK Biobank.
: Not applicable.
: CML is on the Scientific Advisory Board of Myriad Neuroscience and has received honoraria for consultancy from UCB. C.L.-Q. has received consultancy fees from Pfizer. C.L.-Q. has received honoraria, travel or speakers’ fees from Biogen and research funds from Pfizer and Novo Nordisk. C.L.-Q. is the director of the company BrainLogia. All other authors declare no competing interests.
